Amniotics AB (publ) announced that the company has decided to close the phase Ib study of PulmoStem after completing the 2 million cell per kilo bodyweight cohort. Patients with Covid-19 as well as patients with Respiratory Syncytial Virus have been successfully treated. The safety and tolerability of PulmoStem at two dose levels has been evaluated. Given that the study has been completed earlier than planned the study report will be finalised already during the third quarter of 2023. The costs of study-related activities will therefore significantly decrease compared to previous forecasts. There are no safety concerns behind the decision to close the study.
The study results will be integrated into the further development of PulmoStem in fibrotic and inflammatory lung diseases.